Re-Vana Therapeutics Ltd, a Belfast, Northern Ireland, UK-based specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, closed its Series A round with $11.9m in funding.
The round was led by Visionary Ventures with participation from ExSight Ventures, InFocus Capital Partners and existing U.K. investors, Qubis Ltd, Co-Fund NI, and TechStart Ventures. In conjunction with this financing, Re-Vana’s board of directors has been further strengthened by the appointments of Robert Avery, M.D., of Visionary Ventures and InFocus Capital Partners, as board member, and Michael O’Rourke, President and CEO of Re-Vana Therapeutics, as Board Chair.
The company intends to use the proceeds for the development of its novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and for the expansion of operations and development teams.
Founded in 2016 as a spin-out from Queen’s University Belfast, Northern Ireland, Re-Vana Therapeutics is a specialty ocular therapeutic and drug delivery company with headquarters located in Belfast and a U.S.-based office, Re-Vana Therapeutics, Inc., in Tampa, Florida. it is currently developing sustained release ophthalmic therapeutics aimed at reducing the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration (wet AMD). In addition, its proprietary photo-crosslinked sustained-release technology may enable the development of a broad range of novel, sustained release products applicable to a variety of therapeutic areas.
FinSMEs
30/11/2022